Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:Antibe Partnership to Accelerate Drug Pipeline

[mstrmnd]

If you have an IND/DIN for oral treatment of acute pain, it's natural progression to go to chronic pain thereafter

There's absolutely no need to do dose ranging for chronic pain pre-partnership, otherwise could burn through cash when #1 priority IND/DIN is Post-Operative Pain for Otenaproxesul

After successful Phase 2 in Post-Operative Pain, Antibe will have very successul efficacy and safety data for 2 IND/DINs in acute pain ready for partnership and Phase 3 RCTs

This is an acute pain drug company now, that can cross over into chronic pain and IBD post-partnership. 

MrMugsy wrote:

mstrmnd wrote: Based on quality of data from existing studies, I would not be surprised if Antibe partnered with Big Pharma earlier than expected to accelerate entire drug pipeline

Antibe can conduct multiple Phase 3 clinical trials with their pipeline simultaneously with a pharma partner - Antibe took 7 years to get ATB-346 here, with a pharma partner, all 4 of their top patents can be accelerated into their respective markets

GLTA

That certainly is one potential angle and I'd welcome it.
But - I see a required path in order to open that up to us.

346(acute) seems to be straight forward.
352(acute) to also follow suit  - but -  we don't know the specific purpose intended for that drug (yet).

Then - the rest of the pipeline is what we'd call "long term" or chronic type indications (for the most part). 

I think ATE needs to solve 346(chronic) before any partner would be interested in partnering on that pipeline.  IBD, 340, respiratory and others ... all have the same likely issue - liver confusion.

So ... ATE is working on a hypothesis based on what they've learned (and are learning) from liver experts.  Can they solve the liver confusion issue?  

Therefore ...

Bring acute to market - and - show that H2S IP has value.

and

Solve chronic to open up the rest of the funnel to the end-game.


Then ... your angle is viable.  IMO